Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2023 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 31, 2023 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 28, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
August 09, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results

On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA PRAX-628 Phase 1 study showed consistent safety profile and target engagement in...
August 08, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

Patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111) Patients...
August 07, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in the composite qEEG measured through 10-day treatment period Ongoing PRAX-628 Phase 2 Photo-Paroxysmal...
August 03, 2023 16:12 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
June 22, 2023 07:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to...
June 15, 2023 23:58 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
June 15, 2023 16:01 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...